XML 74 R64.htm IDEA: XBRL DOCUMENT v3.22.2
Strategic Alliances (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended 90 Months Ended
Sep. 14, 2021
Jul. 06, 2021
Jun. 18, 2021
May 05, 2020
Oct. 21, 2019
May 31, 2016
Jan. 31, 2015
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Dec. 31, 2021
Jun. 30, 2022
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Total revenues               $ 309,893 $ 442,408 $ 639,111 $ 987,573    
Milestone revenue recognized                   17      
LeaderMed | LeaderMed Joint Venture | Corporate Joint Venture                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Ownership interest in joint venture (as a percent) 47.00%                        
Initial investment in joint venture $ 11,000                        
Ownership percentage by related parties (as a percent) 53.00%                        
CAMP4                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Upfront payment (in shares)   3,373,008                      
Outstanding shares (as a percent)   9.00%                      
Period following first commercial sale in a country   10 years                      
Nicoya                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Upfront payment from development and license agreement     $ 5,000                    
Period after first commercial sale     10 years                    
Initial upfront payment                   5,000      
Pfizer | Products                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Maximum milestone payments             $ 275,000            
Milestone payments               85,000          
Annual height velocity at point in time         12 months                
Initial upfront payment             295,000            
Additional milestone payment             275,000            
Milestone revenue recognized                         $ 85,000
Minimum | Pfizer | Products                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Milestone payments             20,000            
Maximum | Pfizer | Products                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Milestone payments             $ 90,000            
Phase Three Initiation | Nicoya                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Upfront payment from development and license agreement     $ 5,000                    
Regulatory and Development | Nicoya                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Milestone payment from development and license agreement     $ 115,000                    
Transfer of intellectual property and other                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Total revenues               87,197 9,548 93,159 13,816    
Transfer of intellectual property and other | Products                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Total revenues       $ 3,000                  
Transfer of intellectual property and other | LeaderMed | LeaderMed Joint Venture | Corporate Joint Venture                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Total revenues $ 1,000                     $ 1,000  
Transfer of intellectual property and other | CAMP4                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Total revenues   $ 1,500                      
Transfer of intellectual property and other | VFMCRP | Products                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Total revenues                   3,000      
Transfer of intellectual property and other | Pfizer | Products                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Total revenues               2,300 2,800 4,500 5,600    
Maximum milestone payments                   85,000      
Dravet Syndrome Products | CAMP4                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Development milestone payments   3,500                      
Sales milestone payments   $ 90,000                      
Development milestone payments (in shares)   5,782,299                      
Non-Dravet Syndrome Products | CAMP4                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Development milestone payments   $ 4,000                      
Sales milestone payments   $ 90,000                      
Development milestone payments (in shares)   1,082,248                      
Products                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Total revenues               $ 35,892 $ 35,663 $ 72,550 $ 69,608    
Regulatory Milestones | EirGen Pharma Limited                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Maximum milestone payments       17,000                  
Sales Milestones | EirGen Pharma Limited                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Maximum milestone payments       $ 207,000                  
Exclusive Option | VFMCRP                          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                          
Maximum milestone payments           $ 555,000